Global Projects Information

Get latest news on International Projects. Upcoming Global Project News & New Project Information world wise. Search International & Global Projects for Infrastructure work, Power Projects, Energy Sector Oil & Gas Projects, Projects from Government sector, Railway, Water supply & sanitation work across the world. Search latest Global Projects News from Bid Detail.

1.

UNIVERSIDADE NOVA DE LISBOA

Checkpoints in the bacterial cell cycle: role of the cytokinetic Z-ring and implications for antibiotic resistance

  • 15 Million
  • Portugal
view notice less notice
Checkpoints in the bacterial cell cycle: role of the cytokinetic Z-ring and implications for antibiotic resistance
Company Name UNIVERSIDADE NOVA DE LISBOA
Funded By 38
Country Portugal , Western Europe
Project Value 15 Million
Project Detail

The occurrence of multiple-drug resistant bacteria constitutes an important threat to healthy lives, signifying the importance of alternative strategies to combat bacterial infections. This research project bears the potential to significantly contribute to overcome antibiotic resistances that occur during the treatment of bacterial infections, as it combines the studies of cell division, cell cycle regulation and antibiotic resistance in the clinically relevant model Staphylococcus aureus. Given that the tubulin homologue FtsZ is essential for cell division and serves as an antibiotic resistance determinant in this organism, the proposed research activity focuses on the cytokinetic Z-ring, more precisely its role in driving the staphylococcal cell cycle. Super-resolution microscopy will be used to determine if FtsZ treadmilling controls the rate of cytokinesis and if it organizes the peptidoglycan synthesis proteins during cell division, aiming to provide evidence for a FtsZ-dependent checkpoint in the cell cycle. Profiting from a mutant screen currently ongoing in the host laboratory, mutants impaired in the timing of septum formation will be identified to study the functional integration of corresponding genes into FtsZ-driven septum synthesis. In view of the fact that bacteria at different stages of the cell cycle are phenotypically distinct, microfluidics will be used to test if the degree of antibiotic tolerance varies during the cell cycle, which would enforce the vision for re-sensitizing resistant bacteria by manipulating their cell cycle. The strong expertise and the availability of cutting-edge techniques in the host group together with my professional experience will generate an ideal synergy within this work programme. I will generate valuable scientific knowledge, acquire transferrable skills and create new collaborations in the international bacterial cell biology community, thus paving the way for establishing myself as an independent researcher.

Sector Administration & Marketing

Contact Details

Company Name UNIVERSIDADE NOVA DE LISBOA
Address Campus De Campolide 1099 085 Lisboa
Web Site https://cordis.europa.eu/project/rcn/222146/factsheet/en

2.

FUNDACAO CALOUSTE GULBENKIAN

Microbial therapy against gut inflammation

  • 147,815
  • Portugal
view notice less notice
Microbial therapy against gut inflammation
Company Name FUNDACAO CALOUSTE GULBENKIAN
Funded By 38
Country Portugal , Western Europe
Project Value 147,815
Project Detail

Gut microbiota support intestinal tract development, immune system maturation, and protection against pathogens. Imbalanced microbiota (dysbiosis) has a role in inflammatory bowel disease (IBD). To control inflammation, patients take antibiotics, exacerbating dysbiosis, leading to loss of colonization resistance against pathogens and proliferation of pathobionts, disease development and progression. Microbiota composition has, therefore, a very important role in host health, and strategies to manipulate this composition are lacking. Microbiota-produced molecules, like quorum sensing (QS) signal autoinducer-2, can influence gut composition. Bacteria use QS to regulate populational gene expression. We intend to take advantage of microbial interactions mediated by QS to tackle IBD dysbiosis. We will design biotherapies to attenuate the detrimental dysbiotic effects on host health, focusing on gut QS in IBD. The microbiota imbalance observed in IBD leads to high inflammation, expansion of pathobionts, and loss of protection against infections. In previous work, we have shown that by committing the gut microbiota to inter-species QS we could increase members of the microbiota affected by antibiotics, highlighting the potential of QS manipulation to counteract dysbiosis. We propose to manipulate QS of native gut microbes to counteract IBD-associated dysbiosis, and thus inflammation and loss of protection associated with it, rescuing normal microbiota functions. We will tackle dysbiosis by manipulating QS signalling and by fostering specific beneficial interactions amongst microbes. The potential of this therapy, as an alternative or complement to antibiotics, is centred on bypassing the worsening of dysbiosis, like loss of protection against the expansion of inflammation-driving pathobionts and infections, as well as the attenuation of inflammation.

Sector Administration & Marketing

Contact Details

Company Name FUNDACAO CALOUSTE GULBENKIAN
Address Avenida Berna 45 1000 Lisboa
Web Site https://cordis.europa.eu/project/rcn/222392/factsheet/en

3.

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Polyphenols and Gut Microbiota interaction in Cardiovascular Health

  • 172,932
  • Spain
view notice less notice
Polyphenols and Gut Microbiota interaction in Cardiovascular Health
Company Name AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS
Funded By 38
Country Spain , Western Europe
Project Value 172,932
Project Detail

Cardiovascular disease (CVD) is the main cause of mortality in Europe with an annual estimated cost of €210 billion. Different European Public Health strategies have targeted diet to prevent/treat CVDs. This multidisciplinary and multi-institutional project aims to provide new insights into the role of the gut microbiota as a key player in the beneficial effects against CVDs associated with the consumption of Polyphenols (PPs)-rich foods. PolyBiota will be developed through innovative research at one of the epicenters of PPs research (CEBAS-CSIC) and secondment at FISABIO (Valencia, Spain). Epidemiological, clinical, and preclinical studies suggest that the consumption of PPs-containing food protects against CVDs (i.e, modulating angiogenesis in atherosclerotic plaques) . However, these benefits are not always observed due to the high inter-individual variability. The gut microbiota has emerged as an essential player that regulates the bioactivity of PPs. Recent clinical trials indicate that the gut microbiota composition play a critical role in the activity of PPs improving CV biomarkers. These studies open a new door to investigate how the interaction PPs-gut microbiota can modulate mechanisms associated with the improvement of CVDs. PolyBiota will investigate: i) role of the gut microbiota as mediator of the effects of the consumption of Ellagitannins (ETs)-/urolithin (Uro)-A- and Isoflavones (IsoFlv)-/equol-enriched diets on angiogenesis/mechanisms related in untreated and antibiotic-treated animals, ii) the “prebiotic-like effect” of the ETs, Uro-A, IsoFlv and equol consumption on the gut microbiota population, iii) the effects of the gut microbiota-biosynthesized messenguers or the ETs- and IsoFlv-derived metabolites on in vitro tubulogenesis. PolyBiota shows an innovative approach combining cutting-edge techniques, “big data” management, endothelial cells, and in vivo animal models providing a holistic scene of the Diet-Gut Microbiota-Host interaction.

Sector Administration & Marketing

Contact Details

Company Name AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS
Address Calle Serrano 117 28006 Madrid
Web Site https://cordis.europa.eu/project/rcn/222098/factsheet/en

4.

THE UNIVERSITY OF BIRMINGHAM

Elucidating the gene exchange networks of antibiotic resistance genes in clinical sewage microbiomes

  • 212,934
  • United Kingdom
view notice less notice
Elucidating the gene exchange networks of antibiotic resistance genes in clinical sewage microbiomes
Company Name THE UNIVERSITY OF BIRMINGHAM
Funded By 38
Country United Kingdom , Western Europe
Project Value 212,934
Project Detail

"Antibiotics are essential for treating bacterial infections. However, antimicrobial resistance (AMR) has spread among pathogenic bacteria, leading to therapy failure or deaths of patients. Due to their association with promiscuous mobile genetic elements, clinically important antibiotic resistance genes (ARGs) can spread rapidly among diverse bacteria through horizontal gene transfer (HGT). Due to HGT, identifying the microbial hosts of the ARGs in an ecosystem is a challenge. Importantly, it has been shown that ARGS can spread from human gut commensals to clinical pathogens and vice versa. Wastewater from clinical sources can importantly select for HGT of ARGs between different microbes, as both antibiotics and ARGs are present at high levels. The aim of this project - ""ARCS"" (Antibiotic Resistance in Clinical Sewage microbiomes), is to reveal the ARGs exchange networks in clinical sewage microbiomes. The research objectives are: 1) Link ARGs to microbial hosts by using novel culture-independent methods based on DNA high-throughput sequencing. 2) Link ARGs to mobile genetic elements by isolating, sequencing, and characterizing the genomes of the identified hosts of ARGs. 3) Evaluate whether the isolates can transfer their ARGs to clinical pathogens using conjugation assays. ARGS will thus lead to a step-change in our understanding of HGT of ARGs in complex microbial ecosystems. The Fellow Dr. Lisandra Zepedas expertise in generating and analysing DNA sequencing data and the host Prof. Willem van Schaiks international leadership in AMR ensure a successful completion of ARCS and a favourable knowledge transfer for both parties. Furthermore, the supportive environment of the University of Birmingham ensures the accomplishment of the Fellows training in crucial areas such as microbial DNA capture sequencing, microbiology laboratory techniques, and mentoring skills. Thus, ARCS will enable Dr. Zepeda to realise her career goal of becoming a research group leader."

Sector Administration & Marketing

Contact Details

Company Name THE UNIVERSITY OF BIRMINGHAM
Address Edgbaston B15 2tt Birmingham
Web Site https://cordis.europa.eu/project/rcn/221996/factsheet/en

5.

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Bacterial membrane vesicles a novel delivery system for the treatment of multi-drug resistant Gram-negative bacterial infections.

  • 212,934
  • United Kingdom
view notice less notice
Bacterial membrane vesicles a novel delivery system for the treatment of multi-drug resistant Gram-negative bacterial infections.
Company Name IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Funded By 38
Country United Kingdom , Western Europe
Project Value 212,934
Project Detail

"Bacterial infections are a significant public health challenge and a major cause of human mortality globally. Antibiotics are indispensable for the treatment and prevention of infections caused by bacteria. However, global spread of drug-resistant bacteria, coupled with a dearth of new antibiotics in development has led to an alarming shortage of effective drugs. Gram-negative bacteria, in particular, protect themselves against antibiotics with a highly selective outer membrane. The high burden of diseases caused by Gram-negative bacteria, combined with their frequent multi-drug resistance has placed them as world´s highest-priority pathogens by the World Health Organization. Consequently, there is an urgent need for novel therapeutic approaches that combat Gram-negative bacterial pathogens. The goal of ""BacDrug"" is to use lipid-based bacterial membrane vesicles (BMVs) produced by non-pathogenic Lactococcus lactis as delivery system. BMVs have great potential as nanocarriers to by-pass the outer membrane and deliver their toxic payload to kill drug-resistant Gram-negative pathogens. A range of strategies will be used to load BMVs with cargo, including genetic engineering of L. lactis as well as chemical treatments. This Fellowship will harness expertise and techniques across microbiology, molecular biology, nanotechnology and drug design to deliver a successful outcome. The collaborative, truly interdisciplinary, cross faculty setting within the groups of Prof Molly Stevens (materials and bioengineering) and Dr Andrew Edwards (molecular microbiology) at ICL combines world-class expertise and provides an environment to maximise the success of this Fellowship, both in terms of the delivering the project and the training opportunities provided. Moreover, this innovative, alternative strategy to tackle drug-resistant Gram-negative bacterial infections has a high translational potential, which will be exploited via the clinical and translational research clinics at ICL."

Sector Administration & Marketing

Contact Details

Company Name IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Address South Kensington Campus Exhibition Road Sw7 2az London
Web Site https://cordis.europa.eu/project/rcn/222045/factsheet/en

6.

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Comprehensive Mechanisms of Bacterial Antibiotic Tolerance in Mycobacterium Tuberculosis

  • 212,934
  • United Kingdom
view notice less notice
Comprehensive Mechanisms of Bacterial Antibiotic Tolerance in Mycobacterium Tuberculosis
Company Name IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Funded By 38
Country United Kingdom , Western Europe
Project Value 212,934
Project Detail

Mycobacterium tuberculosis (Mtb) is one of about a dozen bacterial species for which some clinical isolates are now resistant to most or all antibiotics (abx) approved for treatment of the infections they cause. Mechanisms of antimicrobial resistance (AMR) in Mtb deserve study for their potential relevance to AMR in other pathogens; because tuberculosis (TB) is now the leading cause of death from infectious disease; and because drug-resistant TB may be the most prevalent of all drug-resistant bacterial infections. Heritable AMR in Mtb emerges with interruption of treatment, and the long duration of TB treatment provides many opportunities for interruption. Prolonged treatment is necessary because of nonheritable resistance, also called phenotypic tolerance or persistence, defined as the transient tolerance of bacteria in an antibiotic-sensitive population to an antibiotic during exposure to an otherwise lethal concentration of that antibiotic. In contrast to “resisters”, whose AMR is genetically encoded, “persisters” are genetically sensitive bacteria whose phenotypic tolerance allows them to survive for prolonged periods during what would otherwise be rapidly curative treatment. In addition, phenotypic tolerance is likely a source of treatment failure and a major contributor to TB reactivation after apparently effective treatment. The specific aims of this application are to identify genetic determinants that foster phenotypic tolerance in Mtb and decipher at a molecular level the mechanisms by which Mtb enters and maintains a persistent state.

Sector Administration & Marketing

Contact Details

Company Name IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Address South Kensington Campus Exhibition Road Sw7 2az London
Web Site https://cordis.europa.eu/project/rcn/221808/factsheet/en

7.

ZENTRUM FUR SONNENENERGIE- UND WASSERSTOFF-FORSCHUNG BADEN-WURTTEMBERG

Development of an innovative sustainable process for simultaneous sewage sludge fluidized bed combustion and REcovery of PHOsphorus in a Ca bed

  • 262,210
  • Germany
view notice less notice
Development of an innovative sustainable process for simultaneous sewage sludge fluidized bed combustion and REcovery of PHOsphorus in a Ca bed
Company Name ZENTRUM FUR SONNENENERGIE- UND WASSERSTOFF-FORSCHUNG BADEN-WURTTEMBERG
Funded By 38
Country Germany , Western Europe
Project Value 262,210
Project Detail

Phosphorus (P) is an essential nutrient and major economic factor. The EU covers its demands by importing Phosphate rock listed as critical raw material due to its scarce resource. Sewage sludge from waste water treatment plants is a promising alternative source of P. RECaPhos focuses on development of a novel method for phosphorus recovery based on the thermo-chemical reaction of sewage sludge, in the presence of CaO in a fluidized-bed reactor, assuring in the same time the destroy of dangerous pathogens, antibiotics and contaminations. Goal is to develop, optimize, and evaluate the novel method and to provide rules and data for process up scaling purposes. This will be achieved by means of development of innovative models to investigate the thermodynamic and chemical process taking place. Experimental data from host institution facilities and data from literature will be used for models validation and optimization. The results will be used as a basis for the design of a demo plant as well as for the identification/evaluation of the process economics and commercialization potential. Two reference cases will be studied, one for a new plant and one for a retrofit of an existing fluidized bed combustion plant. Comparison with other competitive processes will be realized. RECaPHOS is original, highly innovative, and ambitious since the same cheap widely available, natural, non toxic, and environmental friendly Ca-based material is used for P adsorption and subsequent P recycling as it is directly used as feedstock for fertilizer production, closing a natural cycle. RECaPHOS is an excellent and unique opportunity for the researcher who is a mother of two daughters to restart her career after more than 4 years of career break prior to call deadline due to maternity and after resettling back to Europe/Germany after a 3 years continuous stay outside Europe in the last 5 years, in a highly innovative non-profit academic institution that supports women and work life balance.

Sector Administration & Marketing

Contact Details

Company Name ZENTRUM FUR SONNENENERGIE- UND WASSERSTOFF-FORSCHUNG BADEN-WURTTEMBERG
Address Meitnerstrasse 1 70563 Stuttgart
Web Site https://cordis.europa.eu/project/rcn/221746/factsheet/en

8.

SENOVA GESELLSCHAFT FUR BIOWISSENSCHAFT UND TECHNICK MBH

Development of a simple and rapid assay for early diphtheria diagnosis.

  • 174,806
  • Germany
view notice less notice
Development of a simple and rapid assay for early diphtheria diagnosis.
Company Name SENOVA GESELLSCHAFT FUR BIOWISSENSCHAFT UND TECHNICK MBH
Funded By 38
Country Germany , Western Europe
Project Value 174,806
Project Detail

During 1990s, there was an epidemic of diphtheria in Russia and other countries of the former USSR affecting about 200, 000 people with 5000 deaths. Although diphtheria incidence in Russia has declined substantially, recent reports from several EU countries indicate circulation of toxigenic C. diphtheriae among migrants from Asia and Africa as well as children’s deaths among indigenous population. Toxigenic C. diphtheriae poses a serious risk for unvaccinated persons and persons with low level of immunological protection, the number of which in recent times in Europe has increased. The International system of quality control revealed poor state of laboratory diagnosis of diphtheria in EU countries, which means we are not prepared for the possible outbreaks. This is mostly due to the absence of simple, standard and reliable diagnostic methods. The leading element in the diphtheria laboratory diagnostic approach is a detection of the bacterial toxin. In this regard, it is proposed to develop non-apparatus immunochromatographic strip (ICS) test for diphtheria toxin (DT) indication. In addition a liquid selective medium for the clinical sample cultivation will be designed. A combination of the ICS test and the medium will represent a novel assay for early diphtheria diagnosis. The reagent kit will be commercially produced. The availability of simple, reliable and affordable ICS assay for DT detection will increase the accuracy of diphtheria diagnosis in EU and other countries and reduce the duration of its execution up to 6 hours (instead of 5-7 days as recommended by the WHO manual). The efficient early diphtheria diagnosis will enable timely initiation of anti-diphtheritic treatment that will save lives, prevent the development of complications (heart failure, paralysis), as well as stop the spread of the disease through initiation of preventive measures (vaccination and antibiotic prophylaxis) in case of disease outbreaks.

Sector Administration & Marketing

Contact Details

Company Name SENOVA GESELLSCHAFT FUR BIOWISSENSCHAFT UND TECHNICK MBH
Address Industriestr. 8 99427 Weimar
Web Site https://cordis.europa.eu/project/rcn/221731/factsheet/en

9.

SWANSEA UNIVERSITY

Decrypting Mycobacterium cytochrome P450 (CYP) physiological functions by testing hypotheses emitted form large-scale comparative genomics analysis

  • 212,934
  • United Kingdom
view notice less notice
Decrypting Mycobacterium cytochrome P450 (CYP) physiological functions by testing hypotheses emitted form large-scale comparative genomics analysis
Company Name SWANSEA UNIVERSITY
Funded By 38
Country United Kingdom , Western Europe
Project Value 212,934
Project Detail

More than 190 species belong to the Mycobacterium genus. Among those, several are pathogenic to human and animals. The high number of human lives lost and the economic consequences of livestock infection are important incentives in the control and eradication of the responsible organisms. M. tuberculosis, one of the causative agents of tuberculosis (TB), is the most problematic representative: in 2016, 1.7 million deaths worldwide have been attributed to TB. Like for other infectious organisms, antibiotic resistances have appeared in Mycobacterium. Thus, there is a fundamental need to develop new antimycobacterial drugs. The inhibition of enzymes belonging to the Cytochrome P450 (CYP) protein family has been shown to suppresses the growth of several Mycobacterium species, making CYPs targets for drug development. Unfortunately, most CYPs are considered orphan: proteins for which no physiological function is known. The deCrYPtion action aims to define the physiological function of a selected set of mycobacterial CYPs. It will prove determinant in the development of new antibiotics. I will perform a large-scale comparative genomics analysis of the CYPs encoded by Mycobacterium species, in order to define orthologous groups and identify, for each, conserved partners and pathway context. This approach is extremely powerful (even if not frequently used) and allow to propose physiological functions, based on the information obtained. Specific CYPs to be characterized will be selected based on a set of stringent considerations, including their potential as drug targets. A preliminary analysis illustrates the approach that will be used. A combination of complementary biochemical, genetics and physiological experiments will be performed to validate the hypotheses generated. deCrYPtion will be undertaken within the Centre for Cytochrome P450 Biodiversity, under the supervision of Prof Steven Kelly, at Swansea University (Wales, United Kingdom).

Sector Administration & Marketing

Contact Details

Company Name SWANSEA UNIVERSITY
Address Singleton Park Sa2 8pp Swansea
Web Site https://cordis.europa.eu/project/rcn/221669/factsheet/en

10.

UNIVERSITEIT ANTWERPEN

The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

  • 14 Million
  • Belgium
view notice less notice
The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
Company Name UNIVERSITEIT ANTWERPEN
Funded By 38
Country Belgium , Western Europe
Project Value 14 Million
Project Detail

Antimicrobial resistance (AMR) is of great public health concern, causing numerous losses of lives worldwide and threatening to reverse many of the considerable strides modern medicine has made over the last century. There is a need to stratify antibiotic and alternative treatments in terms of the actual benefit for the patient, improving patient outcome and limit the impact on AMR. High quality, effective and appropriate diagnostic tests to steer appropriate use of antibiotics are available. However, implementation of these tests into daily healthcare practice is hampered due to lack of insight in the medical, technological and health economical value and limited knowledge about psychosocial, ethical, regulatory and organisational barriers to their implementation into clinical practice. VALUE-Dx will define and understand these value indicators and barriers to adoption of diagnostics of Community-Acquired Acute Respiratory Tract Infections (CA-ARTI) in order to develop and improve health economic models to generate insight in the whole value of diagnostics and develop policy and regulatory recommendations. In addition, efficient clinical algorithms and user requirement specifications of tests will be developed fuelling the medical and technological value of CA-ARTI diagnostics. The value of diagnostics will be tested and demonstrated in a unique pan-European clinical and laboratory research infrastructure allowing for innovative adaptive trial designs to evaluate novel CA-ARTI diagnostics. Close and continuous interaction with the VALUE-Dx multi-stakeholder platform provides for optimal alignment of VALUE-Dx activities with stakeholder opinions, expert knowledge and interests. A variety of dissemination and advocacy measures will promote wide-spread adoption of clinical and cost-effective innovative diagnostics to achieve more personalized, evidence-based antibiotic prescription in order to transform clinical practice, improve patient outcomes and combat AMR.

Sector Administration & Marketing

Contact Details

Company Name UNIVERSITEIT ANTWERPEN
Address Prinsstraat 13 2000 Antwerpen
Web Site https://cordis.europa.eu/project/rcn/221594/factsheet/en

Filter Projects

Top